WO2026076157A1 - Constructions d'agonistes de notch synthétiques et procédés d'utilisation - Google Patents

Constructions d'agonistes de notch synthétiques et procédés d'utilisation

Info

Publication number
WO2026076157A1
WO2026076157A1 PCT/US2025/049093 US2025049093W WO2026076157A1 WO 2026076157 A1 WO2026076157 A1 WO 2026076157A1 US 2025049093 W US2025049093 W US 2025049093W WO 2026076157 A1 WO2026076157 A1 WO 2026076157A1
Authority
WO
WIPO (PCT)
Prior art keywords
construct
snag
notch
cells
jag1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/049093
Other languages
English (en)
Inventor
Vincent Luca
David Perez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lee Moffitt Cancer Center and Research Institute Inc
Original Assignee
H Lee Moffitt Cancer Center and Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Center and Research Institute Inc filed Critical H Lee Moffitt Cancer Center and Research Institute Inc
Publication of WO2026076157A1 publication Critical patent/WO2026076157A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des procédés et des compositions pour des constructions d'agonistes de Notch synthétiques qui activent la signalisation Notch. Les constructions fournissent une communication cellulaire ciblée pour des applications thérapeutiques et diagnostiques.
PCT/US2025/049093 2024-10-01 2025-10-01 Constructions d'agonistes de notch synthétiques et procédés d'utilisation Pending WO2026076157A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463701952P 2024-10-01 2024-10-01
US63/701,952 2024-10-01

Publications (1)

Publication Number Publication Date
WO2026076157A1 true WO2026076157A1 (fr) 2026-04-09

Family

ID=99358356

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/049093 Pending WO2026076157A1 (fr) 2024-10-01 2025-10-01 Constructions d'agonistes de notch synthétiques et procédés d'utilisation

Country Status (1)

Country Link
WO (1) WO2026076157A1 (fr)

Similar Documents

Publication Publication Date Title
US20230250149A1 (en) Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy
US20250215104A1 (en) Novel soluble urokinase plasminogen activator receptor (supar) binding molecules and uses thereof
US12227590B2 (en) Methods and composition for a binding molecule targeting cancer cells expressing SSX2 peptide 41-49 in HLA-A*0201 context
US20240218053A1 (en) Engineering biologics to hpv oncoproteins
US20220257735A1 (en) A peptide-based screening method to identify neoantigens for use with tumor infiltrating lymphocytes
US20110158953A1 (en) Tumor suppression through plexin c1
WO2026076157A1 (fr) Constructions d'agonistes de notch synthétiques et procédés d'utilisation
US20240091359A1 (en) Novel esr1 derived peptides and uses thereof for neoantigen therapy
US20250163146A1 (en) Single-domain antibodies (nanobodies) targeting the notch ligand dll4 and methods of their use
US20190375842A1 (en) Check point inhibition in organ fibrosis
US8697846B2 (en) Methods of making monoclonal antibodies using fusion-peptide epitope adoptive transfer (F-PEAT) technology
US20240293460A1 (en) Dkk1/hla-a2 binding molecules and methods of their use
US20250282853A1 (en) Utilization of immortalized b cells to identify sdcbp as a novel therapeutic target in ovarian carcinoma
US20230416359A1 (en) Olfactory receptors for use as targets for antigen binding molecules to detect and treat cancer
US20250003954A1 (en) Universal til cytotoxicity assay
US20240182909A1 (en) Checkpoint Aptamers as Therapeutics for Cancer Treatment
WO2025171250A1 (fr) Tcr nyeso1 pour thérapie à base de lymphocytes t et méthodes d'utilisation